Dr. Simons on Racial Disparities Reported in Luminal Breast Cancer


In Partnership With:

Yael Simons, MD, discusses the racial disparities seen in African Americans patients with luminal breast cancer.

Yael Simons, MD, a Hematology/Oncology fellow at the University of Illinois Cancer Center, discusses the racial disparities seen in African Americans patients with luminal breast cancer.

Currently, a lot of data suggest that African American patients experience worse breast cancer outcomes, according to Simons. Previously, these outcomes were attributed to later time of diagnosis, or higher rates of triple-negative disease, which tends to have a poor prognosis, Simons says. More recently, findings have shown that in hormone receptor–positive or luminal breast tumors, there is also a racial disparity, with worse outcomes in African American patients, Simons notes.

A recent study showed that with regard to luminal breast cancers, African American patients have a disease that is more aggressive biologically; they also tend to have worse outcomes with early-stage disease, Simons explains. As such, a study is underway to examine the molecular characterization of these tumors to see whether any insights could help explain these disparities, Simons concludes.

Related Videos
Samilia Obeng-Gyasi, MD, MPH
Tycel Phillips, MD
Ajai Chari, MD
Reshma Jagsi, MD, DPhil, Emory University
Nisha A. Mohindra, MD, Northwestern University Feinberg School of Medicine
Katrina S. Pedersen, MD, MS, associate professor, John T. Milliken Department of Medicine, Division of Oncology, Medical Oncology program leader, cofounder, Young Onset Colorectal Cancer Program, Washington University School of Medicine in St. Louis, Siteman Cancer Center
Dan S. Childs, MD, medical oncologist, Mayo Clinic
Neal Shore, MD, FACS, discusses current and ongoing research with radioligand therapy in patients with nonmetastatic castration-sensitive prostate cancer.
Jane L. Meisel, MD